Roche purchases shares in tender offer for 89bio, Inc
Basel, 30 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary…
89bio was left between a Roche and a hard place in buyout talks
Everyone flirted with 89bio. Only Roche wanted to put a ring on it. In a financial filing, 89bio detailed…
Roche becomes MASH player via $3.5B deal for 89bio, phase 3 drug
Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion…
Swiss pharma firm Roche to acquire US-based biotech firm 89bio for $3.5B
Mucahithan Avcioglu September 18, 2025•Update: September 18, 2025 ISTANBUL Swiss pharmaceutical firm Roche has agreed to acquire US…
Roche to buy Nasdaq-listed 89bio for up $3.5bn
Shares in American clinical-stage biopharmaceutical company 89bio rocketed in pre-market trade on Thursday after Swiss pharma giant Roche…
Roche to Acquire 89bio for $14.50/Share Plus $6 CVR
Roche (OTCQX: RHHBY) has initiated a tender offer to acquire all outstanding shares…
Roche Purchases 89bio Shares at $14.50 Plus Up to $6.00 CVR
Roche (OTCQX: RHHBY) announced that its subsidiary accepted for payment all shares validly…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
Roche purchases shares in tender offer for 89bio, Inc
F. Hoffmann-La Roche Ltd Basel, 30 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that…
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche (RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. (ETNB) for $3.5 billion in a…
Roche To Buy 89bio For Up To $3.5 Billion
Roche, a leading global pharmaceutical company, has announced that it has reached an agreement to acquire 89bio, Inc.,…
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
F. Hoffmann-La Roche Ltd Basel, 1 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that…
Roche poised to buy MASH drug developer 89bio for $3.5bn
Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and…